Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
REGULATORY
Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally endorsed a draft report on June 6, listing a slew of issues faced by the industry and putting forward directions…
To read the full story
Related Article
- Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
- MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
- Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
REGULATORY
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- MHLW Proposes Periodic Survey of Vaccine Prices in Japan
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Japan Extends Re-Examination Period for Entyvio, Zintus
September 11, 2024
- AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…